MAP1B and prostate adenocarcinoma: Furthermore, the analysis of miTGs with GEPIA2 based on The Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD) and the Genotype-Tissue Expression (GTEx) project data demonstrated only for MAP1B a statistically significant higher expression in tumors if compared to normal counterpart in PCa patients.